{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:01:45Z","timestamp":1792425705701,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.jns.2020.116690","type":"journal-article","created":{"date-parts":[[2020,1,18]],"date-time":"2020-01-18T11:12:57Z","timestamp":1579345977000},"page":"116690","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study"],"prefix":"10.1016","volume":"411","author":[{"given":"Tess","family":"Litchman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskar","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine","family":"Njike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jns.2020.116690_bb0005","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.jns.2020.116690_bb0010","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","article-title":"Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4","volume":"12","author":"Verschuuren","year":"2013","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.jns.2020.116690_bb0015","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"issue":"11","key":"10.1016\/j.jns.2020.116690_bb0020","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.jns.2020.116690_bb0025","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.nurt.2008.08.011","article-title":"Current and future standards in treatment of myasthenia gravis","volume":"5","author":"Gold","year":"2008","journal-title":"Neurotherapeutics"},{"issue":"6","key":"10.1016\/j.jns.2020.116690_bb0030","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ncpneuro0810","article-title":"Steroids and immunosuppressant drugs in myasthenia gravis","volume":"4","author":"Sathasivam","year":"2008","journal-title":"Nat. Clin. Pract. Neurol."},{"issue":"6","key":"10.1016\/j.jns.2020.116690_bb0035","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jns.2020.116690_bb0040","first-page":"255","article-title":"Clinical characteristics of refractory myasthenia gravis patients","volume":"86","author":"Suh","year":"2013","journal-title":"Yale J. Biol. Med"},{"issue":"5","key":"10.1016\/j.jns.2020.116690_bb0045","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1756285611411503","article-title":"Response of patients with refractory myasthenia gravis to rituximab: a retrospective study","volume":"4","author":"Nowak","year":"2011","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"3","key":"10.1016\/j.jns.2020.116690_bb0050","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"Diaz-Manera","year":"2012","journal-title":"Neurology."},{"issue":"3","key":"10.1016\/j.jns.2020.116690_bb0055","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/mus.21521","article-title":"Rituximab in the management of refractory myasthenia gravis","volume":"41","author":"Zebardast","year":"2010","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.jns.2020.116690_bb0060","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/CND.0b013e3181fcc109","article-title":"Prolonged improvement after rituximab: two cases of resistant muscle-specific receptor tyrosine kinase + myasthenia gravis","volume":"12","author":"Burusnukul","year":"2010","journal-title":"J. Clin. Neuromuscul. Dis."},{"issue":"2","key":"10.1016\/j.jns.2020.116690_bb0065","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1468-1331.2008.02399.x","article-title":"Successful treatment of refractory generalized myasthenia gravis with rituximab","volume":"16","author":"Lebrun","year":"2009","journal-title":"Eur. J. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.jns.2020.116690_bb0070","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jns.2009.02.357","article-title":"Rituximab for myasthenia gravis: three case reports and review of the literature","volume":"280","author":"Stieglbauer","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2020.116690_bb0075","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jneuroim.2008.04.039","article-title":"Sustained response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients","volume":"201\u2013202","author":"Illa","year":"2008","journal-title":"J. Neuroimmunol."},{"issue":"7","key":"10.1016\/j.jns.2020.116690_bb0080","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/jnnp.2006.093567","article-title":"Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis","volume":"78","author":"Baek","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"7","key":"10.1016\/j.jns.2020.116690_bb0085","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s00415-006-0442-2","article-title":"Rituximab in refractory MuSK antibody myasthenia gravis","volume":"254","author":"Thakre","year":"2007","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2020.116690_bb0090","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mus.20479","article-title":"Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab","volume":"33","author":"Hain","year":"2006","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.jns.2020.116690_bb0095","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaneurol.2016.4190","article-title":"Durability of the rituximab response in acetylcholine receptor autoantibody-positive myasthenia gravis","volume":"74","author":"Robeson","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2020.116690_bb0100","first-page":"e2182","article-title":"B cell targeted treatment in myasthenia gravis (BeatMG): a phase 2 trial of rituximab in myasthenia gravis","volume":"90","author":"Nowak","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2020.116690_bb0105","author":"Nowak"},{"issue":"10","key":"10.1016\/j.jns.2020.116690_bb0110","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology."},{"issue":"8","key":"10.1016\/j.jns.2020.116690_bb0115","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1212\/01.wnl.0000254620.45529.97","article-title":"Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis","volume":"68","author":"Deymeer","year":"2007","journal-title":"Neurology."},{"issue":"2","key":"10.1016\/j.jns.2020.116690_bb0120","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/CND.0b013e318275197c","article-title":"Different characteristic phenotypes according to antibody in myasthenia gravis","volume":"14","author":"Oh","year":"2012","journal-title":"J. Clin. Neuromuscul. Dis."},{"issue":"4","key":"10.1016\/j.jns.2020.116690_bb0125","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.clineuro.2012.06.013","article-title":"The predictive value of the presence of different antibodies and thymus pathology to the clinical outcome in patients with generalized myasthenia gravis","volume":"115","author":"Nikolic","year":"2013","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"10","key":"10.1016\/j.jns.2020.116690_bb0135","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/brain\/awg223","article-title":"Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis","volume":"126","author":"Evoli","year":"2003","journal-title":"Brain."},{"issue":"3","key":"10.1016\/j.jns.2020.116690_bb0140","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1157\/13076937","article-title":"\u201cSeronegative\u201d myasthenia gravis and antiMuSK positive antibodies: description of Spanish series","volume":"125","author":"Illa","year":"2005","journal-title":"Med. Clin."},{"issue":"12","key":"10.1016\/j.jns.2020.116690_bb0145","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","article-title":"Clinical aspects of MuSK antibody positive seronegative MG","volume":"60","author":"Sanders","year":"2003","journal-title":"Neurology."},{"issue":"9","key":"10.1016\/j.jns.2020.116690_bb0150","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.clinph.2005.06.003","article-title":"MuSK-antibody positive myasthenia gravis: clinical and electrodiagnostic patterns","volume":"116","author":"Stickler","year":"2005","journal-title":"Clin. Neurophysiol."},{"issue":"5","key":"10.1016\/j.jns.2020.116690_bb0155","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/01.wco.0000180660.57801.3f","article-title":"Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis","volume":"18","author":"Vincent","year":"2005","journal-title":"Curr. Opin. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2020.116690_bb0160","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1474-4422(03)00306-5","article-title":"Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets","volume":"2","author":"Vincent","year":"2003","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jns.2020.116690_bb0165","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/mus.20069","article-title":"Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients","volume":"30","author":"Zhou","year":"2004","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.jns.2020.116690_bb0170","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of america","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology."},{"issue":"10","key":"10.1016\/j.jns.2020.116690_bb0175","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/ncpneuro0901","article-title":"B cells as therapeutic targets in autoimmune neurological disorders","volume":"4","author":"Dalakas","year":"2008","journal-title":"Nat. Clin. Pract. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2020.116690_bb0180","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.autrev.2009.08.007","article-title":"Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis","volume":"9","author":"Dorner","year":"2009","journal-title":"Autoimmun. Rev."},{"issue":"25","key":"10.1016\/j.jns.2020.116690_bb0185","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.jns.2020.116690_bb0190","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/jnnp.2010.220475","article-title":"Use and monitoring of low dose rituximab in myasthenia gravis","volume":"82","author":"Blum","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"12","key":"10.1016\/j.jns.2020.116690_bb0195","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1136\/jnnp-2012-303664","article-title":"Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients","volume":"84","author":"Keung","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"8","key":"10.1016\/j.jns.2020.116690_bb0200","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/jnnp-2018-319410","article-title":"Long-term follow-up of patients with myasthenia gravis treated with low-dose rituximab","volume":"90","author":"Chan","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.jns.2020.116690_bb0205","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/acn3.564","article-title":"The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis","volume":"5","author":"Cort\u00e9s-Vicente","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2020.116690_bb0210","first-page":"82","article-title":"Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3","volume":"67","author":"R\u00f8dgaard","year":"1987","journal-title":"Clin. Exp. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.jns.2020.116690_bb0215","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jneuroim.2008.01.013","article-title":"Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1","volume":"195","author":"Niks","year":"2008","journal-title":"J. Neuroimmunol."},{"issue":"11","key":"10.1016\/j.jns.2020.116690_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080695","article-title":"MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters","volume":"8","author":"Koneczny","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jns.2020.116690_bb0225","author":"Piehl"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X20300265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X20300265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:49:31Z","timestamp":1758383371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X20300265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":44,"alternative-id":["S0022510X20300265"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2020.116690","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2020.116690","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116690"}}